Haemonetics
294 hedge funds and large institutions have $3.9B invested in Haemonetics in 2022 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 103 increasing their positions, 104 reducing their positions, and 20 closing their positions.
145% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 20
9% more funds holding
Funds holding: 270 → 294 (+24)
2% more capital invested
Capital invested by funds: $3.83B → $3.9B (+$73.2M)
1% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 104
1.32% less ownership
Funds ownership: 100.85% → 99.53% (-1.3%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
56% less call options, than puts
Call options by funds: $3.35M | Put options by funds: $7.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.3M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$36.5M |
| 3 |
BlackRock
New York
|
+$26.9M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$17.4M |
| 5 |
Goldman Sachs
New York
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$107M |
| 2 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
-$38.1M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$26.5M |
| 4 |
Millennium Management
New York
|
-$25.2M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18M |
HAE Hedge Fund Activity: Q4 2022 in Review
294 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2022, worth a combined $3.9B — up 1.9% from $3.83B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new HAE positions and 20 closed out — a net gain of 29 holders — while 103 added to existing stakes and 104 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $48.3M. The largest seller was Wellington Management Group, cutting an estimated $107M.
- 294 institutional investors held Haemonetics (HAE) as of Q4 2022, up from 270 in Q3 2022.
- Funds reported $3.9B of Haemonetics stock for Q4 2022, up 1.9% quarter-over-quarter.
- 49 funds opened new Haemonetics positions in Q4 2022 and 20 closed out, a net change of +29 holders.
- The largest Haemonetics buyer in Q4 2022 was Fidelity Investments, an estimated $48.3M added.
- The largest Haemonetics seller in Q4 2022 was Wellington Management Group, an estimated $107M sold.
Based on aggregated 13F filings for Q4 2022.